New strategy of antiangiogenic therapy for hepatocellular carcinoma

Neoplasma

Volumn 55, Issue 6, 2008, Pages 472-481

  Wu, X Z ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Hepatocellular carcinoma; Hypoxia; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; BETA INTERFERON; BEVACIZUMAB; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; EPIRUBICIN; FARNOQUINONE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OXALIPLATIN; PERINDOPRIL; PERINDOPRILAT; PI 88; SOMATOSTATIN; SORAFENIB; THALIDOMIDE; VANDETANIB; VASCULOTROPIN; VATALANIB; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTIFICIAL EMBOLISM; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG RESPONSE; ECCHYMOSIS; HUMAN; HYPOXIA; IMMUNOTHERAPY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG EMBOLISM; MULTIDRUG RESISTANCE; SHORT SURVEY; THROMBOCYTOPENIA; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; ANIMAL; LIVER TUMOR; NEOVASCULARIZATION (PATHOLOGY); REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 59749083509     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (139)

1. BURROUGHS A, HOCHHAUSER D, MEYER T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 2004; 5: 409-418
2. CUSNIR M, PATT YZ. Novel systemic therapy options for hepatocellular carcinoma. Cancer J. 2004;10:97-103. (Pubitemid 44403475)
3. SUN HC, TANG ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol. 2004; 130: 307-319 (Pubitemid 38858340)
4. SUN B, ZHANG S, ZHANG D et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep. 2006; 16: 693-698
5. SUN HC, TANG ZY, LI XM et al. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol. 1999; 125: 419-426 (Pubitemid 29287501)
6. MOON WS, RHYU KH, KANG MJ et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol. 2003; 16: 552-557
7. GUO RP, ZHONG C, SHI M et al. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006; 132: 547-555
8. YAMAGUCHI R, YANO H, NAKASHIMA O et al. Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2006; 21: 152-160
9. LIU Y, POON RT, LI Q et al. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584, Cancer Res. 2005, 65: 3691-3699
10. GIANNELLI G, AZZARITI A, SGARRA C, PORCELLI L, ANTONACI S, PARADISO A. ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol. 2006; 71: 479-485 (Pubitemid 43077082)
11. ZHU AX, BLASZKOWSKY LS, RYAN DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 1898-1903 (Pubitemid 46638989)
12. GOLLOB JA, WILHELM S, CARTER C et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/ MEK/ERK signal transduction pathway. Semin Oncol. 2006; 33: 392-406.
13. LIU L, CAO Y, CHEN C, ZHANG X et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66: 11851-11858
14. STRUMBERG D, RICHLY H, HILGER RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005; 23: 965-972 (Pubitemid 46202316)
15. ABOU-ALFA GK, SCHWARTZ L, RICCI S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 4293-4300 (Pubitemid 46630787)
16. MOON WS, PARK HS, YU KH et al. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol. 2006; 37: 1324-1332 (Pubitemid 44380277)
17. UEDA S, BASAKI Y, YOSHIE M et al. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res. 2006; 66: 5346-5353
18. MATSUO M, SAKURAI H, SAIKI I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther. 2003; 2: 557-561
19. REYNAERT H, ROMBOUTS K, VANDERMONDE A et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004; 53: 1180-1189 (Pubitemid 38961975)
20. REUBI JC, ZIMMERMANN A, JONAS S et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut. 1999; 45: 766-774 (Pubitemid 29492155)
21. TIAN J, TANG ZY, YE SL et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer. 1999; 81: 814-821
22. JIA WD, XU GL, SUN HC et al. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat Dis Int. 2003; 2: 404-409
23. TREIBER G, WEX T, ROCKEN C et al. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006; 132: 699-708. (Pubitemid 44337930)
24. JIA WD, XU GL, XU RN et al. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol. 2003; 129: 327-334
25. KOUROUMALIS E, SKORDILIS P, THERMOS K et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998; 42 :442-447 (Pubitemid 28197039)
26. YUEN MF, POON RT, LAI CL et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology.2002; 36: 687-691
27. DIMITROULOPOULOS D, XINOPOULOS D, TSAMAKIDIS K et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology. 2002; 49: 1245-1250 (Pubitemid 35052791)
28. LERSCH C, SCHMELZ R, ERDMANN J et al. Treatment of HCC with pravastatin, octreotide, or gemcitabine - a critical evaluation. Hepatogastroenterology. 2004;51: 1099-1103
29. PLENTZ RR, TILLMANN HL, KUBICKA S et al. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage. J Gastroenterol Hepatol. 2005; 20: 1422-1428
30. CEBON J. Australasian Gastro-Intestinal Trials Group (AGITG) Ag0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer. 2006; 95: 853-861
31. BECKER G, ALLGAIER HP, OLSCHEWSKI M et al. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology. 2007; 45: 9-15. (Pubitemid 46144359)
32. DIMITROULOPOULOS D, XINOPOULOS D, TSAMAKIDIS K et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol. 2007; 13: 3164-3170
33. BISSELL DM. Chronic liver injury, TGF-beta, and cancer. Exp Mol Med. 2001; 33: 179-190
34. WU XZ, CHEN D, XIE GR. Extracellular matrix remodeling in hepatocellular carcinoma: effects of soil on seed? Med Hypotheses. 2006; 66: 1115-1120
35. WU XZ. The role of extracellular matrix remodeling in carcinogenesis and metastasis. Med Hypotheses. 2006;67:425. (Pubitemid 43841842)
36. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88: 277-285 (Pubitemid 28015876)
37. MUSSO O, THERET N, HELJASVAARA R et al. Tumor hepatocytes and basement membrane-Producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers. Hepatology. 2001; 33: 868-876
38. MUSSO O, REHN M, THERET N et al. Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res. 2001; 61:45-49
39. SUN FX, TANG ZY, LUI KD et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer. 1996; 66: 239-243 (Pubitemid 26248207)
40. SUN HC, ZHANG M, TANG ZY et al. Endostatin inhibited the growth of human HCC subcutaneously implanted in nude mice. Chin J Exp Surg. 1999; 16: 495-497
41. LIU F, TAN G, LI J, DONG X et al. Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci. 2007 Jul 11; [Epub ahead of print]
42. EDER JP JR, SUPKO JG, CLARK JW et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002; 20: 3772-3784
43. THOMAS JP, ARZOOMANIAN RZ Alberti D et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003; 21: 223-231 (Pubitemid 46606150)
44. HANSMA AH, BROXTERMAN HJ, VAN DER HORST I et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann Oncol. 2005; 16: 1695-1701
45. DVORAK HF. Wounds that do not heal- Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659
46. LEVINE MN, LEE AY, KAKKAR AK. From Trousseau to targeted therapy: New insights and innovations in thrombosis and cancer. J Thromb Haemost 2003; 1: 1456-1463
47. WU XZ, Effects of sulfated polysaccharides on tumor biology. West Indian Med J. J. 2006; 55: 270-273
48. WU XZ. Sulfated oligosaccharides and tumor: promoter or inhibitor? Panminerva Med. 2006; 48: 27-31.
49. SMORENBURG SM, VAN NOORDEN CJ. The complex sffects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001; 53: 93-106.
50. MIAO HQ, LIU H, NAVARRO E et al. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem. 2006; 13: 2101-2111
51. ZHANG Y, LI L, WANG Y et al. Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma. Biochem Biophys Res Commun. 2007; 358: 124-129 (Pubitemid 46719090)
52. PARISH CR, FREEMAN C, BROWN KJ et al. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999; 59: 3433-3441
53. BASCHE M, GUSTAFSON DL, HOLDEN SN et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res. 2006; 12: 5471-5480 (Pubitemid 44497263)
54. Positive Results For Liver Cancer Trial. 2006; 12, 24. http:// www.progen.com.au/
55. FERRO V, DREDGE K, LIU L, HAMMOND E et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost. 2007; 33: 557-568
56. WU XZ, CHEN D, XIE GR. Effects of Gekko sulfated polysaccharide on the proliferation and differentiation of hepatic cancer cell line. Cell Biol Int. 2006; 30: 659-664
57. WU XZ. Cancer and chronic tissue injury: abnormal repair tissue or functional repair tissue?Med Hypotheses. 2006; 67: 676-677
58. PENG SH, DENG H, YANG JF et al. Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol. 2005; 11: 6521-6524
59. MAZZANTI R, MESSERINI L, MONSACCHI L et al. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology. 1997; 25: 229-234 (Pubitemid 27015016)
60. PEREZ-RUIZ M, ROS J, MORALES-RUIZ M et al. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide. Hepatology. 1999; 29: 1057-1063
61. KAWAKITA T, SHIRAKI K, YAMANAKA Y et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun. 2004; 318: 726-733
62. HIRA E, ONO T, DHAR DK et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer. 2005; 103: 588-598
63. REN Y, TSUI HT, POON RT, NG IO et al. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer. 2003; 107: 22-29
64. von MARSCHALL Z, SCHOLZ A, CRAMER T et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003; 95: 437-448 (Pubitemid 36432418)
65. FATHALLAH-SHAYKH HM, ZHAO LJ, KAFROUNI AI et al. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol. 2000; 164: 217-222
66. WANG L, WU WZ, SUN HC et al. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg. 2003; 7: 587-594
67. WANG L, TANG ZY, QIN LX et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology. 2000; 32: 43-48
68. OGASAWARA S, YANO H, MOMOSAKI S et al. Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo. J Interferon Cytokine Res. 2007; 27: 507-516
69. FURUMOTO K, ARII S, YAMASAKI S et al. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int J Cancer. 2000; 87: 665-672
70. BARAJAS M, MAZZOLINI G, GENOVE G et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology. 2001; 33: 52-61.
71. HARADA N, SHIMADA M, OKANO S et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol. 2004; 173: 6635-6644
72. CHADA S, SUTTON RB, EKMEKCIOGLU S et al. MDA-7/IL-24 is a unique cytokine-tumor suppressor in the IL-10 family. Int Immunopharmacol. 2004; 4: 649-667
73. PESTKA S, KRAUSE CD, SARKAR D, WALTER MR, SHI Y, FISHER PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004; 22: 929-979
74. WANG X, YE Z, ZHONG J, XIANG J, YANG J. Adenovirus-mediated Il-24 expression suppresses hepatocellular carcinoma growth via induction of cell apoptosis and cycling arrest and reduction of angiogenesis. Cancer Biother Radiopharm. 2007; 22: 56-63.
75. CERVELLO M, FODERAA D, FLORENA AM et al. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol. 2005; 11: 4638-4643
76. KONDO M, YAMAMOTO H, NAGANO H et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res. 1999; 5: 4005-4012
77. Cheng AS, Chan HL, To KF, et al. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol. 2004; 24: 853-860
78. RAHMAN MA, DHAR DK, YAMAGUCHI E et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible in volvement of COX-2 in the angiogenesis of hepatitis C viruspositive cases. Clin Cancer Res. 2001; 7: 1325-1332
79. ZHAO QT, YUE SQ, CUI Z et al. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci. 2007; 80: 484-492
80. CERVELLO M, MONTALTO G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol. 2006; 12: 5113-5121
81. YOSHIJI H, YOSHII J, IKENAKA Y et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol. 2002; 20: 1227-1231
82. YOSHIJI H, KURIYAMA S, KAWATA M et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res. 2001; 7: 1073-1078
83. YOSHIJI H, KURIYAMA S, FUKUI H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002; 23: 348-356
84. YOSHIJI H, KURIYAMA S, NOGUCHI R et al. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol. 2005; 42: 687-693 (Pubitemid 40501686)
85. YOSHIJI H, KURIYAMA S, NOGUCHI R et al. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep. 2006; 15: 155-159
86. YOSHIJI H, NOGUCHI R, YAMAZAKI M et al. Combined treatment of vitamin K(2) and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis. World J Gastroenterol. 2007; 13: 3259-3261
87. LOWNDES SA, HARRIS AL. The role of copper in tumour angiogenesis. J Mammary Gland Biol Neoplasia. 2005; 10:299-310.
88. EAGON PK, TEEPE AG, ELM MS et al. Hepatic hyperplasia and cancer in rats: alterations in copper metabolism. Carcinogenesis. 1999; 20: 1091-1096
89. EBARA M, FUKUDA H, HATANO R et al. Relationship between copper, zinc and metallothionein in hepatocellular carcinoma and its surrounding liver parenchyma. J Hepatol. 2000; 33: 415-422
90. YOSHII J, YOSHIJI H, KURIYAMA S et al. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer. 2001; 94: 768-773
91. YOSHIJI H, KURIYAMA S, YOSHII J et al. The copper-chelating agent, trientine, attenuates liver enzyme-altered preneoplastic lesions in rats by angiogenesis suppression. Oncol Rep. 2003; 10: 1369-1373
92. SONE K, MAEDA M, WAKABAYASHI K et al. Inhibition of hereditary hepatitis and liver tumor development in Long- Evans cinnamon rats by the copper-chelating agent trientine dihydrochloride. Hepatology. 1996; 23: 764-770 (Pubitemid 126664271)
93. MORIGUCHI M, NAKAJIMA T, KIMURA H et al. The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer. 2002; 102: 445-452
94. CALABRESE L, FLEISCHER AB. Thalidomide current and potential clinical applications. Am J Med 2000; 108: 487-495 (Pubitemid 30214201)
95. MORIERA AL, SAMPAIO EP, ZMUIDZINAS A et al. Thalidomide exerts its inhibitory action on tumor necrosis factor [alpha] by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680
96. GAD SM, SHANNON EJ, KROTOSKI WA et al. Thalidomide induces imbalances in T-lymphocyte subpopulations in the circulating blood of healthy males. Lepr Rev 1985; 56: 35-39
97. HASLETT PA, CORRAL LG, ALBERT M et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+subset. J Exp Med 1998; 187: 1885-1892
98. VERBON A, JUFFERMANS NP, SPEELMAN P et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrobl Agents Chemotherr 2000; 44: 2286-2290
99. HSU C, CHEN CN, CHEN LT et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology. 2003; 65: 242-249 (Pubitemid 37505832)
100. WANG TE, KAO CR, LIN SC et al. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10: 649-653 (Pubitemid 38351529)
101. SCHWARTZ JD, SUNG M, SCHWARTZ M et al. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist. 2005; 10: 718-727
102. PATT YZ, HASSAN MM, LOZANO RD et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005; 103: 749-755 (Pubitemid 40216403)
103. LIN AY, BROPHY N, FISHER GA et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer. 2005; 103: 119-125 (Pubitemid 39665464)
104. HAN SH, PARK SH, KIM JH et al.Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. Korean J Intern Med. 2006; 21: 225-229
105. CHIOU HE, WANG TE, WANG YY, LIU HW.Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol. 2006; 12: 6955-6960 (Pubitemid 44834885)
106. CHUAH B, LIM R, BOYER M et al.Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol. 2007; 46: 234-238 (Pubitemid 46272616)
107. SHIAH HS, CHAO Y, CHEN LT et al. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2006; 58: 654-664 (Pubitemid 44167391)
108. HANAHAN D, FOLKMAN J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-354
109. GASPARINI G, LONGO R, FANELLI M et al. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol. 2005; 23: 1295-1311
110. GRAEPLER F, VERBEEK B, GRAETER T et al. Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology. 2005; 41: 879-886
111. YANASE K, YOSHIJI H, IKENAKA Y et al. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep. 2007; 17: 441-446
112. ZHU AX, FUCHS CS, CLARK JW et al. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005;10:392-398 (Pubitemid 40993567)
113. YOSHIJI H, NOGUCHI R, KURIYAMA S et al. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. Oncol Rep. 2005; 13: 491-495
114. NOGUCHI R, YOSHIJI H, KURIYAMA S et al. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res. 2003; 9: 6038-6045
115. MA L, LUO L, QIAO H et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol. 2007; 46: 98-106.
116. DHAR DK, ONO T, YAMANOI A et al. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer. 2002; 95: 2188-2195
117. SUN HC, ZHANG M, TANG ZY et al. Endostatin inhibited growth and metastasis of human HCC transplanted in nude mice after resection. Chin J Oncol. 2000; 22: 80-81
118. XIA JL, YANG BH, TANG ZY et al. Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma, J Cancer Res Clin Oncol. 1997; 123: 383-387
119. LOGOTHETIS CJ, WU KK, FINN LD et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen- independent prostate cancer. Clin Cancer Res. 2001; 7: 1198-1203 (Pubitemid 32708670)
120. KIN M, TORIMURA T, UENO T et al. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol. 2000; 16: 375-382
121. KINOSHITA S, HIRAI R, YAMANO T et al. Angiogenesis inhibitor TNP-470 can suppress hepatocellular carcinoma growth without retarding liver regeneration after partial hepatectomy. Surg Today. 2004; 34: 40-46
122. GREENE AK, WIENER S, PUDER M et al. Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg. 2003; 237: 530-535 (Pubitemid 38176434)
123. YI J, LIAO X, YANG Z et al. Study on the changes in microvessel density in hepatocellular carcinoma following transcatheter arterial chemoembolization. J Tongji Med Univ. 2001; 21: 321-2, 331.
124. POON RT, LAU C, YU WC et al. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep. 2004; 11: 1077-1084
125. YANG ZF, POON RT, LIU Y et al. High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis. Mol Cancer Ther. 2006; 5: 2261-2270
126. WU HP, FENG GS, LIANG HM et al. Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. World J Gastroenterol. 2004; 10: 813-818
127. MUGITANI T, TANIGUCHI H, TAKADA A et al. TNP-470 inhibits collateralization to complement the anti-tumour effect of hepatic artery ligation. Br J Cancer. 1998; 77: 638-642
128. BOX AH, DEMETRICK DJ. Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines. Carcinogenesis. 2004; 25: 2325-2335 (Pubitemid 39625172)
129. GWAK GY, YOON JH, KIM KM et al. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol.2005; 42: 358-364
130. KIM KW, BAE SK, LEE OH et al. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 1998; 58: 348-351 (Pubitemid 28047078)
131. PIRET JP, LECOCQ C, TOFFOLI S et al. Hypoxia and CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp Cell Res. 2004; 295: 340-349
132. MATTEUCCI E, MODORA S, SIMONE M et al. Hepatocyte growth factor induces apoptosis through the extrinsic pathway in hepatoma cells: favouring role of hypoxia-inducible factor-1 deficiency. Oncogene. 2003; 22: 4062-4073
133. PIRET JP, MOTTET D, RAES M et al. CoCl2, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann N Y Acad Sci. 2002; 973: 443-447
134. MAZURE NM, NGUYEN TL, DANAN JL. Severe hypoxia specifically downregulates hepatocyte nuclear factor-4 gene expression in HepG2 human hepatoma cells. Tumour Biol. 2001; 22: 310-317
135. WU XZ, XIE GR, CHEN D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol. 2007 Jun 7; [Epub ahead of print]
136. WARTENBERG M, LING FC, MUSCHEN M et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J. 2003; 17: 503-505
137. ZHU H, CHEN XP, LUO SF et al . Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res. 2005; 24: 565-574
138. LIU B, PAN S, DONG X et al. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 2006; 97: 675-681
139. TAN B, HUANG JF, WEI Q et al. Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats. World J Gastroenterol. 2005; 11: 5938-5943